Genome Biologics
PrivateLast Round
VC Round
Dec 20, 2021
Total Funding Raised
$3.01M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Genome Biologics operates in Healthcare & Life Sciences and is based in Frankfurt. Its latest recorded funding round was a VC Round in December 2021.
Genome Biologics is a biotechnology company that provides human cardiac organoid services for drug discovery, cardiac safety pharmacology, and disease modeling.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genome Biologics Comparables
Compare Genome Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HeartBeat.bio AG | 90% | |
| Ncardia | 83% | |
| Dynomics | 82% |
For institutional investors. Book with your work email.
Genome Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 20, 2021 | ||||
| Grant | Sep 1, 2018 |
For institutional investors. Book with your work email.
Genome Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Union's Horizon Research and Innovation program | Grant |
| European Innovation Council Fund | VC Round |
| Johnson & Johnson Innovation - JLABS | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 39% MoM.
- Jan 20, 2026
Monthly visitors increased 1527% MoM.
For institutional investors. Book with your work email.
Genome Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genome Biologics's valuation, stock price, and market status.
Is Genome Biologics a public or private company?
Genome Biologics is a private company.
What is the current stock price of Genome Biologics?
Genome Biologics is a private company, so its shares have no public market price. Caplight tracks Genome Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genome Biologics worth (valuation)?
Valuation information for Genome Biologics is not publicly available.
Can I buy Genome Biologics stock?
Genome Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genome Biologics's last funding round?
Genome Biologics's most recent funding round was VC Round on December 20, 2021.
Who are the main investors in Genome Biologics?
Key investors in Genome Biologics include European Union's Horizon Research and Innovation program, European Innovation Council Fund, Johnson & Johnson Innovation - JLABS.
Will Genome Biologics IPO soon?
No public IPO plans have been announced for Genome Biologics.
How can I track Genome Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Genome Biologics's shares on secondary markets.